Figure 4.
Figure 4. Nonrelapse mortality of patients treated either with HD-RIT using 131I-tositumomab and ASCT or C-HDT and ASCT.

Nonrelapse mortality of patients treated either with HD-RIT using 131I-tositumomab and ASCT or C-HDT and ASCT.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal